Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
|
Eliglustat (Cerdelga®) |
NHSE commissioned |
|
|
|
Elosulfase lfa (Vimizim®) |
NHSE commissioned |
|
|
|
Eltrombopag tablets | ||
|
|
Encorafenib (Braftovi®) | ||
|
|
Encorafenib with binimetinib | ||
|
|
Enoxaparin Injection |
For all other indications. The APC's view is that on clinical grounds, the status for certain indications approved by APC should be amber, supported by an ESCA. However, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain red (ESCAs to be developed). |
|
|
|
Entrectinib | ||
|
|
Enzalutamide capsules | ||
|
|
Enzalutamide capsules#8.3 |
For hospital use only |
|
|
|
Eosin solution 2% w/v |
Unlicensed special |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- Next page
- Last page
